Update:
SBIR and CAP companies are now eligible to apply for the two new
Funding Opportunity Announcements (FOAS) that will be supported by funds provided
to the NIH under the American Recovery & Reinvestment Act of 2009 (“Recovery
Act” or “ARRA”):
- Biomedical
Research, Development, and Growth to Spur the Acceleration of New Technologies
(BRDG-SPAN) Pilot Program (RC3)
- The requested budget
is limited to $1 million total costs per year for a maximum of three years
- Small
Business Catalyst Awards for Accelerating Innovative Research (R43)
- Budget requests are
limited to $200,000 total costs for a maximum project period of one year.
Click
here for more information. Application submission is due September 1,
2009.
Welcome to the NIH Commercialization Assistance Program (NIH-CAP)! The program
is in its fifth year. It is designed to help some of the nation's most promising
small companies in the life sciences in introducing their SBIR-funded technologies
into the marketplace. NIH has engaged the services of Larta Institute (www.larta.org)
to help implement the program. The program is customized to meet the needs of
early stage and seasoned companies in two distinct tracks, Commercialization
Training Track (CTT), and Accelerator Commercialization Track (ACT),
respectively. Each is different in their objectives and outcomes. Details about
the NIH-CAP Program and its two tracks, CTT & ACT, are available in the
Program Description.
For more information, please
visit the Application
Instructions. To apply, please
Register your company.
Since this program has
many new elements, we are currently updating information in some sections of
the site. In the meantime, if you have any questions, please contact Judy Hsieh,
Programs Manager, Larta Institute, at jhsieh@larta.org
or call 213.538.1444.
You need
Internet Explorer 7 or Mozilla
Firefox 3 to navigate this website.
|